Cetuximab for treatment of metastatic colorectal cancer.
暂无分享,去创建一个
M. Moroni | A. Sartore-Bianchi | S. Siena | R. Ricotta | G. Cerea | I. Schiavetto | M. R. Maugeri | S. Artale
[1] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .
[2] J. Tabernero,et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. , 2005 .
[3] A. Halpern,et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.
[4] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[5] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Meyerhardt,et al. Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.
[7] Deborah Schrag,et al. The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.
[8] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Ferlay,et al. Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .